


**Product Name** : T-1101 tosylate  
**Cat. No.** : PC-20310  
**CAS No.** : 2250404-95-4  
**Molecular Formula** : C<sub>31</sub>H<sub>31</sub>N<sub>5</sub>O<sub>6</sub>S<sub>3</sub>  
**Molecular Weight** : 665.80  
**Target** : Hec1/Nek2  
**Solubility** : 10 mM in DMSO



## Biological Activity

T-1101 tosylate (TAI-95 tosylate) is a potent, orally bioavailable Hec1 inhibitor that disrupts **Hec1-Nek2** protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).

T-1101 tosylate demonstrates strong inhibition of in vivo tumor growth of breast cancer models without inducing weight loss or other obvious toxicity.

T-1101 tosylate induces apoptotic cell death, shows activity on MDR cell lines and leads to downregulation of the expression of P-glycoprotein (Pgp).

T-1101 tosylate also increases the potency of cytotoxic Pgp substrates, including doxorubicin and topotecan.

T-1101 tosylate showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration.

## References

Huang LY, et al. *Mol Cancer Ther.* 2014 Jun;13(6):1419-30.

Chuang SH, et al. *Eur J Med Chem.* 2020 Apr 1;191:112118.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com